БОРД ОФ РИДЖЕНТС; ДЗЕ ЮНИВЕРСИТИ ОФ ТЕХАС СИСТЕМ (US)
发明人:
И Цин (US),ЧЖЭН Юйхуань (US)
申请号：
RU2013126798/15
公开号：
RU2013126798A
申请日:
2011.11.11
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating multiple myeloma in a subject, comprising administering to the subject an amount of (1) 5- (2.6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine and / or a stereoisomer, tautomer, or pharmaceutically acceptable salts thereof, and the number (2) dexamethasone and / or a pharmaceutically acceptable salt, solvate, metabolite or the racemate, thereby subekta.2 treatment. A method of treating multiple myeloma in a subject, comprising administering to the subject an amount of (1) 5- (2.6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine and amounts ( 2) dexamethasone, resulting in treatment subekta.3. A method according to Claim. 1 or 2, characterized in that the treatment comprises the co-administration number (1) and the number (2) .4. A method according to Claim. 1 or 2, characterized in that the volume (1) and volume (2) are in a single composition or dosage forme.5. A method according to Claim. 1 or 2, characterized in that the volume (1) and volume (2) are in separate compositions or unit dosage formah.6. A method according to Claim. 1 or 2, characterized in that the treatment comprises substantially simultaneously administering an amount of (1) and the number (2) .7. A method according to Claim. 1 or 2, characterized in that the treatment comprises administering an amount of (1) and the number (2) at different vremya.8. A method according to Claim. 1 or 2, characterized in that the volume (1) and / or the amount of (2) are administered in doses that would not be effective when administered to one or both of (1) and (2) separately but are effective kombinatsii.9. A pharmaceutical composition comprising a quantity of (1) 5- (2.6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine and / or its stereoizome1. Способ лечения множественной миеломы у субъекта, включающий введение в организм субъекта количества (1) 5-(2,6-ди-морфолин-4-ил-пиримидин-4-ил)-4-трифторметил-пиридин-2-иламина и/
